Urothelial cancer
Conditions
Interventions
Palonosetron: day1 0.75mg (i.v.) Aprepitant: day1 125mg, 2-3 80mg (p.o.) Dexamethasone: day1 9.9mg (i.v.)
Sponsors
Urology, Department of Medicine Kitasato University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who need anticonvulsants therapy 2) Vomiting, or CTCAE grade 2 or higher nausea 3) History of hypersensitivity for Palonosetron and/or Aprepitant and/or Dexamethasone 4) Pregnant or lactating women or women of childbearing potential 5) Receiving medicine that has antiemetic activity 6) Patient who doesn't have ability or intention that cooperates for procedure of the study 7) Not appropriate for the study at the physician's assessment
Exclusion criteria
Exclusion criteria: 1) Patients who need anticonvulsants therapy 2) Vomiting, or CTCAE grade 2 or higher nausea 3) History of hypersensitivity for Palonosetron and/or Aprepitant and/or Dexamethasone 4) Pregnant or lactating women or women of childbearing potential 5) Receiving medicine that has antiemetic activity 6) Patient who doesn't have ability or intention that cooperates for procedure of the study 7) Not appropriate for the study at the physician's assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response Rate in overall phase(0-120 hours after chemotherapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Response Rate in acute and delayed phase Complete Control Rate in overall, acute and delayed phase The proportion of patients without nausea in overall, acute and delayed phase Safety | — |
Countries
Japan
Contacts
Public ContactKazumasa Matsumoto
Department of Medicine Kitasato University, School of Medicine Urology
Outcome results
None listed